<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.

ABSTRACT:

Introduction

Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.Over the last 10 years, patient outcomes have improved. However, this is less apparent in older, less fit patients, who are ineligible for stem cell transplant. Research is required in this patient group, taking into account frailty and aiming to improve: treatment tolerability, clinical outcomes and quality of life.

Methods and analysis

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma is a national, phase III, multicentre, randomised controlled trial comparing standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with ixazomib, lenalidomide and dexametha

SUBMITTER: Coulson AB 

PROVIDER: S-EPMC9163533 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature